Pharmacokinetic evaluation of two different formulations of megestrol acetate in patients with advanced malignancies

C. M. Camaggi, E. Strocchi, A. Martoni, C. Zamagni, N. Cacciari, G. Robustelli della Cuna, L. Pavesi, M. Tedeschi, A. Silva, F. Pannuti

Research output: Contribution to journalArticlepeer-review

Abstract

The bioequivalence of two megestrol acetate formulations, 160-mg "tablets" and 160-mg "sachets", was investigated in a single-dose, open-label, balanced-for-sequence cross-over study involving 12 advanced-cancer patients. The observed plasma megestrol-acetate time course obtained with both formulations was consistent with the literature data. The main source of variability in the pharmacokinetic parameters was intersubject variability; drug formulation played only a minor (and nonsignificant) role. The width of the 90% confidence interval of the areaunder-the-curve (AUC) ratio (sachets: tablets) computed according to Schuirmann (0.9-1.4) was mainly due to the presence of a single outlier, showing an AUC ratio of 2.7. The trend to higher bioavailability of the new formulation was not significant, especially as compared with the doseresponse data reported in the literature.

Original languageEnglish
Pages (from-to)356-359
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Volume36
Issue number4
DOIs
Publication statusPublished - Jul 1995

Keywords

  • Bioequivalence
  • Megestrol acetate
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Pharmacokinetic evaluation of two different formulations of megestrol acetate in patients with advanced malignancies'. Together they form a unique fingerprint.

Cite this